High Prednisone Doses for Cancer Immunotherapy Side Effects Linked to Shorter Survival

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to fight cancer cells, leading to dramatically lengthened survival for many patients. However, this powerful class of drugs often comes with a significant drawback: the development of immune-related adverse events (irAEs). These irAEs occur when the newly activated immune cells, instead of solely targeting cancer, begin to attack healthy tissues, leading to autoimmune conditions that can affect almost any organ system. Among the various irAEs, rheumatic manifestations, such as inflammatory arthritis, polymyalgia rheumatica-like phenotypes, myositis, and sicca syndrome, are common and can range from mild to severe. These conditions can significantly impact a patient's quality of life and may even persist long after the discontinuation of ICI therapy. Managing these rheumatic irAEs effectively without compromising the anti-tumor benefits of ICIs or introducing excessive steroid-related toxicities presents a complex challenge for clinicians. The primary treatment for most irAEs, including rheumatic ones, involves systemic glucocorticoids like prednisone. While effective in suppressing inflammation and autoimmune responses, the dosage and duration of prednisone use are critical considerations due to its extensive side effect profile. A recent French study, presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting in 2026 and reported by MedPage Today, has shed light on the potential dangers of high-dose prednisone in this context. The study analyzed records of 103 cancer patients treated between 2015 and 2024 at a major French hospital for ICI-related arthritic symptoms. The findings indicated a concerning association between higher prednisone doses and reduced patient survival. Specifically, cancer patients who received more than 20 mg of prednisone (or its equivalent) at any point to treat these arthritic side effects experienced a significantly shortened overall survival. The study reported a more than doubled overall mortality risk (Hazard Ratio 2.35, 95% CI 1.18-4.69) in patients with a peak daily prednisone-equivalent dose exceeding 20 mg, compared to those who never received such high doses. Adding to the concern, the researchers, led by Eleonore Mourre, MD, of Hôpital Bicêtre in Paris, found that these higher doses of prednisone did not result in better control or remission of the arthritic symptoms. This suggests that the increased risk associated with higher doses of prednisone does not even come with a proportional therapeutic benefit for the rheumatic irAEs. It is important to acknowledge the limitations of this study, as noted by Dr. Mourre, including its single-center design and relatively small sample size. Data regarding the specific reasons for administering high steroid doses were also not available in the analysis. However, these findings align with broader clinical concerns about the delicate balance required when using corticosteroids in cancer patients. Previous research has indicated that doses of 10 mg prednisone equivalent per day or higher at the initiation of ICI treatment may be associated with poorer anti-tumor responses, affecting overall response rate, progression-free survival, and overall survival. General guidelines for managing ICI-induced inflammatory arthritis often recommend starting with moderate doses of prednisone, typically 10-20 mg daily. For mild cases, non-steroidal anti-inflammatory drugs (NSAIDs) or intra-articular corticosteroid injections may be considered. Higher doses, such as 0.5 to 1 mg/kg/day, are reserved for Grade 2 toxicities, and 1 to 2 mg/kg/day for Grade 3 toxicities, with a slow tapering regimen as symptoms resolve. Expert consensus from a survey of rheumatologists suggested that 63% would initiate prednisone at 20 mg or less for moderate irAE-induced inflammatory arthritis, although a significant portion would go higher (30-60 mg) for more active disease. The well-documented side effects of prednisone further underscore the need for judicious use. Long-term and high-dose corticosteroid therapy can lead to a myriad of adverse effects, including osteoporosis (thinning bones), poorly controlled diabetes, glaucoma, cataracts, hypertension (high blood pressure), fluid retention, weight gain, increased susceptibility to infections, muscle weakness (steroid-induced myopathy), mood swings, and adrenal gland dysfunction. Corticosteroid-induced myopathy, for instance, typically develops with doses over 10 mg/day for more than four weeks. Given the complexities, a multidisciplinary approach involving oncologists and rheumatologists is crucial for optimal management of these patients. This collaborative effort helps to balance the need for effective irAE treatment with the preservation of cancer efficacy and the mitigation of steroid-related toxicities. The MedPage Today article, reporting on this study, serves as a timely reminder for healthcare professionals globally, including those in India, about the critical need to carefully consider prednisone dosing in cancer patients receiving ICIs. It reinforces the principle of using the lowest effective dose for the shortest possible duration to manage irAEs, thereby aiming to improve both the rheumatic outcomes and the overall survival of cancer patients. The story's relevance to India's audience is high, given the increasing incidence of cancer and the adoption of advanced cancer therapies like ICIs, leading to a rise in associated irAEs.

Frequently Asked Questions

Read Full Story on Quick Digest